


COPY OF PAPER
ORIGINALLY FILED



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Collin E. Thomas *et al.*

Serial No.: 10/047,251

Filed: January 14, 2002

For: GENETIC AND EPIGENETIC
MANIPULATION OF ABC
TRANSPORTERS AND ECTO-
PHOSPHATASES FOR THE
CONFERENCE OF DRUG RESISTANCE
AND FOR THE LOSS OF DRUG
RESISTANCE IN BIOLOGICAL
SYSTEMS AND METHODS FOR THE
DETECTION OF ECTO-PHOSPHATASE
INHIBITORS

Group Art Unit: 1651

Examiner: Unknown

Atty. Dkt. No.: TEXG:003USD1

RECEIVED
OCT 08 2002
TECH CENTER 1600/2900

CERTIFICATE OF MAILING
37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

September 26, 2002

Date

Robert E. Hanson

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/TEXG:003USD1.

This application is a divisional application of Serial No. 09/261,825, filed March 3, 1999 and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d) copies of the listed documents are not enclosed as they have been previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. 09/261,825.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Robert E. Hanson
Reg. No. 42,628
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: September 26, 2002

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

TEXG:003USD1

10/047,251

Oct 3 2002
O I P E
List of Patents and Publications for Applicant's
INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Applicant
Collin E. Thomas *et al.*

RECEIVED

Filing Date:
January 14, 2002Group:
1651

OCT 08 2002

U.S. Patent Documents
*See Page I*Foreign Patent Documents
*See Page I*Other Art
See Page I

TECH CENTER 1600/2900

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B2	WO 97/30667	8/28/97	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C25	Barros <i>et al.</i> , "Ectonucleotide diphosphohydrolase activities in entamoeba histolytica," <i>Arch. Biochem. Biophys.</i> , 375(2):304-314, 2000.
	C26	Crack <i>et al.</i> , "Pharmacological analysis of ecto-ATPase inhibition: evidence for combined enzyme inhibition and receptor antagonism in P2x-purinoceptor ligands," <i>Br. J. Pharmacol.</i> , 113(4):1432-1438, 1994.
	C27	Crack <i>et al.</i> , "Pharmacological and biochemical analysis of FPL 67156, a novel, selective inhibitor of ecto-ATPase," <i>Br. J. Pharmacol.</i> , 114(2):475-481, 1995.
	C28	Kiba <i>et al.</i> , "Specific inhibition of cell wall-bound ATPases by fungal suppressor from Mycosphaerella pinodes," <i>Plant Cell Physiol.</i> , 36(5):809-817, 1995.
	C29	Okada <i>et al.</i> , "Diethyl pyrocarbonate is an inhibitor of cardiac, intestinal and renal ecto-ATPase," <i>Acta Histochem. Cytochem.</i> , 30(5&6): 637-642, 1997.
	C30	Rengelshausen <i>et al.</i> , "Inhibition of procine renal ecto-ATPase by Ca ²⁺ antagonists," <i>Eur. J. Physiol.</i> , 429(6), Suppl Abstract 177, 1995.
	C31	Thomas <i>et al.</i> , "Apyrase functions implant phosphate nutrition and mobilizes phosphate from extracellular ATP," <i>Plant Physiol.</i> , 119(2):543-551, 1999.
	C32	Yegutkin <i>et al.</i> , "Steady-state binding of [3H]-ATP to rat liver plasma membranes and competition by various purinergic agonists and antagonists," <i>Biochim. Biophys. Acta</i> , 1373(1):227-236, 1998.

25213029.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.